title: Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.
abstract: Since the pioneering work of Patel and Terazaki, the presence of an anti-donor anti-body of the IgG isotype, as demonstrated by a lymphocytotoxic assay on T cells, has been a contraindication to transplantation, due to the very high rate of graft loss reported (>80% in the first few weeks posttransplant). The advent of more sensible and specific techniques of detection of anti-HLA antibodies (such as ELISA or Luminex techniques) has questioned this dogma, with a number of reports showing that transplantation, despite the presence of an donor-specific antibody (DSA), could be done without excessive graft losses, despite higher rates of rejection. We thus decided to retrospectively screen a cohort of 237 patients consecutively transplanted in our unit. This study analyzes the influence of preformed DSA, identified by HLA-specific ELISA assays, on graft survival and evaluates the incidence of antibody-mediated rejection (AMR). Kidney graft survival at 8 years was significantly worse in patients with DSA. The incidence of AMR in patients with DSA was 9-fold higher than in patients without DSA and led to a significantly worse graft survival. The prevalence for AMR in patients with DSA detected on historic serum was 32.3% and was significantly more elevated in patients with strongly positive DSA (score 6-8) and in patients with his-toric positive crossmatches. Interestingly, those patients with DSA that did not experience AMR had the same graft survival as patients without DSA. Thus, the presence of preformed DSA is strongly associated with increased graft loss in kidney transplants, related to an increased risk of AMR. Our findings demonstrate the importance of detection and charac-terization of DSA before transplantation. Stratification of this immunological risk should be used both to determine kidney allocation and to devise specific strategies for these patients.
authors.affiliation: Department of Nephrology and Renal Transplant, Hôpital Saint-Louis 1 Av Claude Vellefaux, FR-75010 Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Lefaucheur
authors.forename: C
authors.initials: C
authors.lastname: Suberbielle-Boissel
authors.forename: G S
authors.initials: GS
authors.lastname: Hill
authors.forename: D
authors.initials: D
authors.lastname: Nochy
authors.forename: J
authors.initials: J
authors.lastname: Andrade
authors.forename: C
authors.initials: C
authors.lastname: Antoine
authors.forename: C
authors.initials: C
authors.lastname: Gautreau
authors.forename: D
authors.initials: D
authors.lastname: Charron
authors.forename: D
authors.initials: D
authors.lastname: Glotz
mesh_terms: D005260:Female; D006084:Graft Rejection / Q000453:epidemiology*; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000097:blood / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D006680:HLA Antigens; D007518:Isoantibodies